As a pharmacological target, the KOR has recently gained attention for its role in modulating myelination and neuroinflammation [4,5,6,7,8], with KOR agonists offering potential as a first-in-class remyelination treatment for demyelinating diseases such as multiple sclerosis. The gene discussed is OPRK1; the disease is multiple sclerosis.